Investment analysts at StockNews.com began coverage on shares of InspireMD (NYSE:NSPR - Get Free Report) in a research note issued to investors on Monday. The brokerage set a "sell" rating on the stock.
Separately, Lake Street Capital started coverage on shares of InspireMD in a report on Wednesday, December 11th. They issued a "buy" rating and a $5.00 price target on the stock.
Check Out Our Latest Research Report on NSPR
InspireMD Stock Up 1.6 %
Shares of NSPR stock traded up $0.05 during trading on Monday, hitting $2.86. The company had a trading volume of 71,092 shares, compared to its average volume of 35,378. The stock's 50-day moving average is $2.85 and its two-hundred day moving average is $2.76. The stock has a market capitalization of $74.47 million, a price-to-earnings ratio of -3.81 and a beta of 0.88. InspireMD has a 52 week low of $1.81 and a 52 week high of $3.80.
Institutional Trading of InspireMD
Hedge funds have recently bought and sold shares of the company. Parkman Healthcare Partners LLC raised its stake in shares of InspireMD by 721.2% during the fourth quarter. Parkman Healthcare Partners LLC now owns 854,716 shares of the company's stock worth $2,248,000 after acquiring an additional 750,635 shares in the last quarter. Essex Investment Management Co. LLC purchased a new position in InspireMD in the 4th quarter worth $191,000. Northern Trust Corp lifted its stake in InspireMD by 103.7% in the fourth quarter. Northern Trust Corp now owns 48,022 shares of the company's stock worth $126,000 after purchasing an additional 24,452 shares during the last quarter. Schonfeld Strategic Advisors LLC boosted its position in InspireMD by 153.2% during the fourth quarter. Schonfeld Strategic Advisors LLC now owns 30,133 shares of the company's stock valued at $79,000 after buying an additional 18,233 shares during the period. Finally, Legato Capital Management LLC purchased a new position in shares of InspireMD in the fourth quarter worth about $47,000. Institutional investors own 44.78% of the company's stock.
InspireMD Company Profile
(
Get Free Report)
InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.
See Also
Before you consider InspireMD, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and InspireMD wasn't on the list.
While InspireMD currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
